Biomarkers associated with lung function decline and dupilumab response in patients with moderate-to-severe asthma
I. Pavord (Oxford, United Kingdom), G. Brusselle (Ghent, Belgium), D. Jackson (Madison, WI, United States), C. Brightling (Leicester, United Kingdom), A. Papi (Ferrara, Italy), J. Maspero (Buenos Aires, Argentina), K. Rabe (Grosshansdorf, Kiel, Germany), S. Korn (Mainz, Germany), M. Zhang (Bridgewater Township, NJ, United States), N. Pandit-Abid (Bridgewater Township, NJ, United States), M. Hardin (Cambridge, MA, United States), L. De Prado Gómez (Reading, United Kingdom), J. Jacob-Nara (Bridgewater Township, NJ, United States), P. Rowe (Bridgewater Township, NJ, United States)
Source: International Congress 2022 – Update on clinical trials in allergy, asthma and COPD
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Pavord (Oxford, United Kingdom), G. Brusselle (Ghent, Belgium), D. Jackson (Madison, WI, United States), C. Brightling (Leicester, United Kingdom), A. Papi (Ferrara, Italy), J. Maspero (Buenos Aires, Argentina), K. Rabe (Grosshansdorf, Kiel, Germany), S. Korn (Mainz, Germany), M. Zhang (Bridgewater Township, NJ, United States), N. Pandit-Abid (Bridgewater Township, NJ, United States), M. Hardin (Cambridge, MA, United States), L. De Prado Gómez (Reading, United Kingdom), J. Jacob-Nara (Bridgewater Township, NJ, United States), P. Rowe (Bridgewater Township, NJ, United States). Biomarkers associated with lung function decline and dupilumab response in patients with moderate-to-severe asthma. 3210
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|